

(English version)

**Question for written answer E-000608/25
to the Commission
Gerald Hauser (P/E)
(11 February 2025)**

Subject: New EU bulk order for 146 million doses of Moderna COVID-19 vaccine

Countless doses of mRNA COVID-19 vaccines have been discarded all over the world because they have expired or are not deemed suitable for new variants. The Commission has now placed a new order with Moderna for more than 146 million doses. It is unclear how much this order will cost and it is questionable whether it is really needed. What is more, the many side effects of the other mRNA vaccines have yet to be analysed. Many doses could be discarded yet again, which would cost taxpayers money without bringing any real benefits. It is rumoured that the Health Emergency Preparedness Response Authority (HERA) signed the contract on behalf of 17 participating countries.

1. Which Member States have ordered Moderna vaccines and who signed the procurement contract?
2. Why are vaccines being ordered once more — by way of an opaque procurement procedure — even though it is not certain that the doses will not end up discarded again and simply cost taxpayers more money?
3. What studies have been carried out on the newly ordered vaccine to confirm that it is safe and effective?

Submitted: 11.2.2025

**Answer given by Ms Lahbib on behalf of the European Commission
(22 April 2025)**

1. The list of participating countries is available in the contract award notice that was published on 24 January 2025 ⁽¹⁾. The framework contract was signed by the Commission on behalf of the participating countries.
2. As the Commission pointed out in its reply to Written Question P-000356/2024 ⁽²⁾, the framework contract signed with Moderna in January 2025 is fully flexible and does not bind the contracting authorities to make any purchase. Indeed, the volume of 146 million doses is the maximum ceiling that contracting authorities could purchase if they would have a need during the whole duration of the framework contract. In order to establish the ceiling, the Commission has consulted the contracting authorities prior to launching the call for tender and asked them about their estimated possible needs in case of crisis.
3. The Spikevax (Moderna COVID-19 vaccine) received a marketing authorisation based on a thorough review by the European Medicine Agency (EMA), of clinical evidence confirming a favourable benefit-risk profile ⁽³⁾. The vaccine was initially assessed in around 30 000 adults and over 3 000 children ⁽⁴⁾. Adapted versions targeting emerging variants, like JN.1, are also approved based on data showing their ability to induce an immune response that can predict clinical efficacy and safety ⁽⁵⁾. EMA monitors EudraVigilance data ⁽⁶⁾ from millions of vaccinated people, reviewing safety information from clinical studies, medical literature and periodic safety update reports to identify and investigate safety signals.

⁽¹⁾ <https://ted.europa.eu/en/notice/-/detail/51540-2025>

⁽²⁾ https://www.europarl.europa.eu/doceo/document/P-9-2024-000356-ASW_EN.html

⁽³⁾ https://www.ema.europa.eu/en/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf

⁽⁴⁾ <https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax>

⁽⁵⁾ <https://pubmed.ncbi.nlm.nih.gov/39591137/>

⁽⁶⁾ <https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance>